VIRxSYS and National Heart, Lung, and Blood Institute Sign Agreement
January 17, 2008 14:03 ET
|
VIRxSYS
GAITHERSBURG, Md., Jan. 17, 2008 (PRIME NEWSWIRE) -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, today announced that they have signed a...
VIRxSYS Announces Acquisition of Intronn
September 21, 2007 09:39 ET
|
VIRxSYS
GAITHERSBURG, Md., Sept. 21, 2007 (PRIME NEWSWIRE) -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, today announced that it has acquired all the...
VIRxSYS Presents Update On HIV Gene Therapy Clinical Trial At ICAAC
September 18, 2007 13:15 ET
|
VIRxSYS
CHICAGO, Sept. 18, 2007 (PRIME NEWSWIRE) -- VIRxSYS Corporation, a privately held company developing genetic therapies for HIV and genetic diseases, announced today the presentation of a new analysis...
Gerard McGarrity Joins VIRxSYS as Executive Vice President of Scientific and Clinical Affairs
February 20, 2007 09:15 ET
|
VIRxSYS
GAITHERSBURG, Md., Feb. 20, 2007 (PRIME NEWSWIRE) -- VIRxSYS Corporation announced today that Gerard McGarrity, Ph.D., has joined the company as Executive Vice President of Scientific and Clinical...
VIRxSYS Raises $20 Million in Financing
December 13, 2006 09:00 ET
|
VIRxSYS
GAITHERSBURG, Md., Dec. 13, 2006 (PRIME NEWSWIRE) -- VIRxSYS Corporation, a privately held company developing genetic therapies for HIV and cancer, announced a $20 million series G round of financing...
VIRxSYS Corporation Announces Publication of Phase I Study of Novel Gene Therapy for HIV
November 06, 2006 17:00 ET
|
VIRxSYS
GAITHERSBURG, Md., Nov. 6, 2006 (PRIMEZONE) -- VIRxSYS Corporation announced today the publication of results from their Phase I, open-label, non-randomized clinical trial evaluating VRX496, a...